Syn2bio (WAR:S2B) Other Stockholders Equity: zł68.53 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:S2B Syn2bio SA WAR:S2B
11 GF Score
Price zł81.40
! 2 Warning Signs
View Full Analysis

What is Syn2bio Other Stockholders Equity?

Syn2bio WAR:S2B +1.88% 11 Other Stockholders Equity is zł68.53 Mil as of Sep. 2025. GuruFocus rates WAR:S2B with a GF Score™ of 11/100. The stock has 2 warning signs investors should review.

Syn2bio's Other Stockholders Equity for the quarter that ended in Sep. 2025 was zł68.53 Mil.

Syn2bio's quarterly Other Stockholders Equity increased from Sep. 2023 (zł23.28 Mil) to Sep. 2024 (zł47.04 Mil) and increased from Sep. 2024 (zł47.04 Mil) to Sep. 2025 (zł68.53 Mil).

Syn2bio's annual Other Stockholders Equity increased from Sep. 2023 (zł23.28 Mil) to Sep. 2024 (zł47.04 Mil) and increased from Sep. 2024 (zł47.04 Mil) to Sep. 2025 (zł68.53 Mil).

Syn2bio Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Syn2bio's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syn2bio Other Stockholders Equity Chart

Syn2bio Annual Data
Trend Sep23 Sep24 Sep25
Other Stockholders Equity
23.28 47.04 68.53

Syn2bio Semi-Annual Data
Sep23 Sep24 Sep25
Other Stockholders Equity 23.28 47.04 68.53
WAR:S2B
11GF Score
Syn2bio SA WAR:S2B
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Syn2bio Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of zł68.53 Mil mean?
Syn2bio (WAR:S2B) has a Other Stockholders Equity of zł68.53 Mil as of Sep. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Syn2bio and its competitors.
Is Syn2bio's Other Stockholders Equity too high?
Syn2bio's current Other Stockholders Equity is zł68.53 Mil. Overall, Syn2bio has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Syn2bio's Other Stockholders Equity compare to VRTX and REGN?
Syn2bio's Other Stockholders Equity of zł68.53 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Syn2bio and its competitors. Syn2bio's current Other Stockholders Equity is zł68.53 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syn2bio stock overvalued right now?
Syn2bio (WAR:S2B) has a current Other Stockholders Equity of zł68.53 Mil. The current Other Stockholders Equity is zł68.53 Mil. Syn2bio's overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Syn2bio (WAR:S2B), the current Other Stockholders Equity is zł68.53 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Syn2bio Business Description

Address ul. Jozefa Piusa Dziekonskiego 3, Warszawa, POL, 00-728
Syn2bio SA is a Polish biotech company that develops radiopharmaceuticals. It specializes in developing a cardiac biomarker for diagnosing heart conditions like coronary artery disease through myocardial perfusion imaging. The company's flagship product is the SYN2 cardiotracer. It is applied in the detection of perfusion disorders, evaluation of patients after myocardial infarction or with ischemic heart disease, and assessment of atherosclerotic changes in coronary arteries.
11GF Score

Get the complete analysis for WAR:S2B

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł81.40
Price